MedLife S.A.

Transaction in Own Shares • Feb 17, 2025

No. 15 / 17 February 2025

To: BUCHAREST STOCK EXCHANGE FINANCIAL SUPERVISORY AUTHORITY

CURRENT REPORT

Current report drafted according to the stipulations of ASF Regulation no. 5/2018 on issuers of financial instruments and market operations and Law no. 24/2017 on issuers of financial instruments and market operations

Report Date: 17 February 2025

Name of the issuing company: MED LIFE S.A. ("MedLife" or "The Company")

Registered Office: Bucharest, Calea Grivitei, no. 365, district 1, Romania

Telephone / Fax number: 0374 180 470

Unique Registration Code at the National Office of Trade Registry: 8422035

Order number on the Trade Registry: J40/3709/1996

Subscribed and paid-in share capital: 132,870,492 RON

Total number of shares: 531,481,968 (out of which 427,042 shares without voting rights and 531,054,926 shares with voting rights)

Regulated market on which the issued securities are traded: Bucharest Stock Exchange, Premium Category

Significant events to report:

In accordance with ASF Regulation no. 5/2018 and art. 2 of the Commission Delegated Regulation (EU) 1052/2016, MED LIFE S.A. reports to the regulated market the following transactions performed for M symbol during 10 – 14 February 2025:

Intermediary of transactions: BT Capital Partners S.A.

Reason for the notification of the transactions: buy-back of MedLife own ordinary shares in accordance with EGSM Decision no. 1 from 3 August 2023.

Transaction Date	Nature of transaction	Trading place	Aggregate volume	Weighted average price/share (RON)	Value (RON)
10.02.2025	Buy-Back	Regulated market	-	-	-
11.02.2025	Buy-Back	Regulated market	-	-	-
12.02.2025	Buy-Back	Regulated market	-	-	-
13.02.2025	Buy-Back	Regulated market	-	-	-
14.02.2025	Buy-Back	Regulated market	-	-	-
Total			-	-	-

Summary of transactions during 10 – 14 February 2025:

Detailed transactions for the 10 – 14 February 2025 period:

No shares buy-back transactions were performed during 10 – 14 February 2025.

Mihail Marcu Chief Executive Officer

________________